Trulieve Begins Trading on the NYSE Today — The First U.S. Cannabis Company to Do It

TALLAHASSEE — At the opening bell this morning, Trulieve Cannabis became the first U.S. plant-touching cannabis operator to trade on a major American stock exchange. The Florida-based multi-state operator’s subordinate voting shares began trading on the New York Stock Exchange under the ticker TRLV — a moment the industry has been chasing, in one form or another, for more than a decade.

It is a genuine milestone. Canadian cannabis producers have held listings on the Nasdaq and NYSE for years, provided they kept their operations out of the United States. No American company that actually grows, processes, and sells cannabis inside the country had crossed that line — until today.

But the path to the Big Board required a significant architectural compromise, and the cannabis industry’s celebration comes with a footnote worth reading carefully.

The Split That Made It Possible

To qualify for NYSE listing, Trulieve did not bring its whole company to market. It surgically carved its adult-use recreational operations out into a separate entity called Harvest Enterprises, bringing in an outside investor — Whitley Holding — for roughly $14.8 million in exchange for a 10% voting stake. That transaction was large enough, under accounting rules, to make the split legally and structurally real.

What lists on the NYSE this morning is the medical-only Trulieve. The recreational weed business — the adult-use cannabis that generates enormous volume in states like Arizona, Pennsylvania, and Maryland — stays parked in Harvest Enterprises, outside the public company entirely. A contractual conversion right allows the recreational operations to fold back into the listed entity if and when federal rules permit recreational operators onto senior exchanges.

The move is architecturally elegant and politically telling. It reflects where the federal government’s cannabis thaw has actually stopped: Schedule III reclassification for medical use, with recreational still firmly in Schedule I limbo.

The April Opening

None of this would have been possible 14 months ago. The Justice Department issued a final reclassification order in April, moving state-licensed medical cannabis from Schedule I to Schedule III — acting on an executive order President Trump signed in December. That single regulatory move cracked open two doors simultaneously: exchange eligibility for medical operators, and relief from the punishing 280E tax provision.

Section 280E of the Internal Revenue Code, a 1970s-era rule written for drug traffickers, bars companies that deal in Schedule I or II controlled substances from deducting ordinary business expenses — payroll, rent, utilities — from their taxable income. The effective tax rate for cannabis operators under 280E can reach 70%, compared to the standard corporate rate of 21%. Trulieve’s new medical entity escapes 280E; the recreational side, still Schedule I, does not.

CEO Kim Rivers has made no secret of who she credits. “Common sense action by President Trump to reclassify medical marijuana to Schedule III paved the way for this historic milestone,” she said in a statement last week.

Rivers has skin in this outcome: Trulieve poured $150 million into Florida’s failed 2024 adult-use legalization ballot initiative, a campaign that came up short. The Schedule III pathway offered a faster, if narrower, route to legitimacy.

Trulieve’s Medical Moat

The split works financially because Trulieve’s medical business is genuinely dominant. The company operates 206 dispensaries and controls an estimated 40% of Florida’s medical cannabis market — enough scale that the medical entity stands as a credible, standalone investment even stripped of recreational revenue.

OTC shares of TCNNF jumped roughly 20% on the uplist announcement June 5 and are up approximately 42% this year heading into today’s open. Whether TRLV holds that enthusiasm once institutional investors can properly underwrite the split structure — medical cash flows separated from recreational upside — will be the market’s first real answer to how it values legal cannabis in 2026.

The Rest of the Industry Is Sprinting

Trulieve’s NYSE debut is not happening in a vacuum. Curaleaf and Verano both announced reverse stock splits this week, moves designed to meet the NYSE’s minimum share-price requirements. The scramble signals that Trulieve’s listing is less a singular achievement than a starting gun for the larger MSO sector.

The DEA holds a scheduled hearing June 29 on whether Schedule III reclassification should extend to recreational cannabis as well. That decision would blow the Harvest Enterprises structure wide open — suddenly, the box holding Trulieve’s adult-use operations would have a path back into the listed company, and the industry’s recreational giants would have their own shot at senior exchange listings.

Until then, the NYSE has cannabis — just the version the federal government is currently willing to sanction.

The bell rang this morning. The rest of the debate is still being written in Washington.

CannabisInquirer.com covers cannabis policy, industry, and culture. Breaking news tips: tips@cannabisinquirer.com